Diagnostic Accuracy of Combined Perfusion Index, Internal Jugular Vein Collapsibility Index and Cardiac Index in Predicting Post-Spinal Hypotension During Elective Cesarean Section
Diagnostic Accuracy of Combined Perfusion Index, Internal Jugular Vein Collapsibility Index and Cardiac Index in Predicting Post-Spinal Hypotension During Elective Cesarean Section: A Prospective Randomized Study
compare Perfusion Index with Internal Jugular Vein Collapsibility Index (IJVCI) as a predictor for post-spinal hypotension in parturient undergoing elective caesarean section.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
- Pre-anesthetic evaluation (History-Investigation - Examination) the day before surgery.
- NPO: 8 hours for solids, 2 hours for clear fluids.
- Pre-medication: Ranitidine 50 mg IV + Metoclopramide 10 mg IV, 30 minutes before anesthesia.
- 18-G IV cannula in the non-dominant forearm.
- Standard monitoring in the operating room: pulse oximetry (SpO2), NIBP, and ECG.
- Baseline measurements (HR, SBP, DBP, MAP, SpO2, PI, CI, IJVCI) recorded in the supine position with 15 degree left lateral tilt.
- All indicators will be measured in a single group before spinal anesthesia and comparisons will be made for the most sensitive maneuver in prediction of post spinal hypotension.
- Cardiac Index (CI) will be measured using cardiometry before spinal anesthesia.
- Perfusion Index (PI) is measured (Three consecutive readings are recorded at 1-minute intervals, will be repeated with another reading after delivery of baby).• The cut-off applied is: -
- 3.5 or less (low risk for hypotension)
- Greater than 3.5 (high risk for hypotension)
- Internal Jugular Vein Collapsibility Index will be measured by Ultrasonographic assessment and is performed by using a 6-10 MHz linear ultrasound probe. (The patient is placed supine with 15 degree left lateral tilt, The probe is positioned horizontally at the right side of the neck at the level of the middle thyroid cartilage, obtaining a transverse view of the right IJV. M-mode imaging during both spontaneous and deep breathing).
- Anteroposterior diameters of the IJV were estimated during the respiratory cycle. The IJV collapsibility index (IJVCI) was estimated via the following equation: Maximum diameter - lowest diameter/maximum diameter) 100% .
- The mean of three consecutive measurements is recorded for each breathing mode in quite respiratory cycle.
- Images will be saved for offline analysis.
- The cut-off applied is:
IJVCI < 35-38% → lower risk of post-spinal hypotension IJVCI ≥ 38-40% → higher likelihood of hypotension after spinal anesthesia in CS.
- Spinal anesthesia with intrathecal drug regimen 10-12 mg of 0.5% hyperbaric bupivacaine plus 25 micrograms (mic) Fentanyl].
- Co-loading with Ringer's lactate at 10ml/Kg will be administrated, along with spinal anesthesia placement .Data Collection
Baseline:
- Patient demographic data (age, ASA physical status, comorbidities, current medications, and BMI).
- Hemodynamics (Heart rate- Mean Arterial Blood Pressure - Systolic Blood Pressure -Oxygen Saturation) baseline reading before induction of spinal anesthesia.
- Preoperative IJVCI measurement by ultrasound imaging in supine position.
- Preoperative Perfusion Index reading.
- Preoperative Cardiac index reading.
Intraoperative:
-
Hemodynamic parameters (SBP, DBP, MAP, HR, SpO2) are recorded: -
- Every 1 minute for the first 10 minutes,
- Every 3 minutes until delivery,
- Every 5 minutes thereafter until end of surgery.
-
Total phenylephrine dose in microgram & Total Ephedrine dose (mg) [if persistent hypotension].
-
Total IV fluid volume (mL)
-
Total Blood loss (mL)
-
Total Urine output (mL)
-
Time from spinal block to delivery (min)
-
Total time of surgery.
-
All adverse events (nausea, vomiting, hypotension, bradycardia, oxygen desaturation) are recorded throughout.
Definition of Outcomes All outcome definitions are pre-specified and uniformly applied across all patients: -
- Post-spinal hypotension: A fall in systolic blood pressure (SBP) below 90 mmHg.
- Episodes are recorded from the time of spinal injection until delivery of the baby.
- Bradycardia: Heart rate below 50 beats per minute requiring pharmacological treatment with atropine 0.01 mg/kg IV.
Treatment of PSH
- First-line: 200 mL Ringer's lactate rapid IV infusion.
- If SBP remains below 90 mmHg phenylephrine 25-100 microgram if persistent hypotension gives Ephedrine 5-15 mg IV bolus.
- Bradycardia (HR < 50 bpm): Atropine 0.01 mg/kg IV.
- All vasopressor doses and additional fluid volumes administered are recorded.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Nevine Soliman, MD
- Numero di telefono: 201128861471
- Email: mostafanevine@gmail.com
Luoghi di studio
-
-
-
Alexandria, Egitto
- Reclutamento
- Menoufia University,Faculty of Medicine
-
Contatto:
- Nevine Soliman, MD
- Numero di telefono: 201128861471
- Email: mostafanevine@gmail.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Adults undergoing Elective Cesarean Section at Menoufia University Hospitals
Descrizione
Inclusion Criteria:
-
Full-term pregnant women undergoing elective cesarean section under spinal anesthesia (gestational age >= 37 weeks), singleton pregnancy.
- Age: 18-40 years.
- ASA I, II.
- BMI: 18.5-35 kg/m2.
Exclusion Criteria:
-
• Patient refusal or inability to provide informed consent.
- Emergency cesarean section.
- Known contraindications to spinal anesthesia (coagulopathy, local infection, elevated ICP).
- Baseline hypotension (SBP < 100 mmHg) prior to spinal anesthesia.
- Hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, eclampsia).
- Placenta previa or antepartum hemorrhage.
- Multiple pregnancy or known fetal abnormality.
- BMI > 35 kg/m2.
- Pre-existing cardiovascular, cerebrovascular, or significant pulmonary disease.
- Gestational diabetes or uncontrolled systemic disease.
- Hemoglobin < 8 g/dL or known haemoglobinopathy.
- Peripheral vascular disease affects pulse oximetry signal quality.
- More than two attempts at lumbar puncture or failed.
- Inadequate spinal block.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Perfusion Index (PI) group measured by pulse oximeter
|
is measured using a validated multi-parameter monitor with a pulse oximetry module (Mindray uMEC 12 or equivalent).
|
|
Internal Jugular Vein Collapsibility Index group will be measured by ultrasonography
IJVCI < 35-38% → lower risk of post-spinal hypotension IJVCI ≥ 38-40% → higher likelihood of hypotension after |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
compare the diagnostic accuracy assessed by ROC curve analysis between Perfusion Index (PI) & Internal Jugular Vein Collapsibility Index (IJVCI) combined with Cardiac Index (CI) in predicting post-spinal hypotension in elective CS patients.
Lasso di tempo: • Three consecutive readings are recorded at 1-minute intervals. • These steps will be repeated with another reading after delivery of baby.
|
• Three consecutive readings are recorded at 1-minute intervals. • These steps will be repeated with another reading after delivery of baby.
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
measure systolic arterial blood pressure changes after spinal anesthesia.
Lasso di tempo: immediately after spinal anesthesia
|
immediately after spinal anesthesia
|
|
Total ephedrine dose or phenylephrine dose /milligram.
Lasso di tempo: throughout the operation
|
throughout the operation
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 9/2026 ANET 53
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .